Search
 
Acquired Platelet Dysfunction

Acquired platelet dysfunction, which is common, may result from aspirin, other NSAIDs, or systemic disorders.

Acquired abnormalities of platelet function are very common. Causes include

  • Drugs
  • Systemic disorders
  • Cardiopulmonary bypass

Acquired platelet dysfunction is suspected and diagnosed when an isolated prolongation of bleeding time is observed and other possible diagnoses have been eliminated. Platelet aggregation studies are unnecessary.

Drugs: AspirinSome Trade Names
BUFFERIN
ECOTRIN
GENACOTE
Click for Drug Monograph
and other NSAIDs, which are very commonly used drugs, may induce platelet dysfunction. Sometimes this effect is incidental (eg, when the drugs are used to relieve pain and inflammation) and sometimes therapeutic (eg, when aspirinSome Trade Names
BUFFERIN
ECOTRIN
GENACOTE
Click for Drug Monograph
is used for prevention of stroke or coronary thrombosis). Other therapeutic antiplatelet drugs include clopidogrelSome Trade Names
PLAVIX
Click for Drug Monograph
, ticlopidineSome Trade Names
TICLID
Click for Drug Monograph
, and the glycoprotein IIb/IIIa inhibitors.

AspirinSome Trade Names
BUFFERIN
ECOTRIN
GENACOTE
Click for Drug Monograph
and NSAIDs prevent cyclooxygenase-mediated production of thromboxane A2. This effect can last 5 to 7 days. AspirinSome Trade Names
BUFFERIN
ECOTRIN
GENACOTE
Click for Drug Monograph
modestly prolongs bleeding time in healthy people but may markedly prolong bleeding time in patients with underlying platelet dysfunction or a severe coagulation disturbance (eg, patients receiving heparinSome Trade Names
HEPFLUSH-10
Click for Drug Monograph
, patients with severe hemophilia).

Systemic disorders: Many disorders (eg, myeloproliferative and myelodysplastic disorders, uremia, macroglobulinemia and multiple myeloma, cirrhosis, SLE) can impair platelet function.

Uremia may prolong bleeding via unknown mechanisms. If bleeding is observed clinically, bleeding time may be corrected transiently with vigorous dialysis, cryoprecipitate administration, or desmopressinSome Trade Names
DDAVP
STIMATE
Click for Drug Monograph
infusion. If indicated for treatment of anemia, RBC count can be increased by transfusion or by giving erythropoietin; this process also shortens the bleeding time.

Cardiopulmonary bypass: Platelets may become dysfunctional, prolonging the bleeding time as blood circulates through a pump oxygenator during cardiopulmonary bypass. The mechanism appears to be activation of fibrinolysis on the platelet surface with resultant loss of the glycoprotein Ib-IX binding site for von Willebrand's factor. Regardless of platelet count, patients who bleed excessively after cardiopulmonary bypass and who have a long bleeding time are transfused with platelets. Giving aprotininSome Trade Names
TRASYLOL
Click for Drug Monograph
(a protease inhibitor that neutralizes plasmin activity) during bypass may preserve platelet function, prevent prolongation of bleeding time, and reduce the need for transfusion.

Last full review/revision May 2009 by James N. George, MD

Content last modified May 2009

Back to Top

Previous: Overview of Platelet Disorders

Next: Hereditary Intrinsic Platelet Disorders

Audio
Figures
Photographs
Tables
Videos

Copyright     © 2010-2011 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, N.J., U.S.A.    Privacy    Terms of Use